Biodistribution of lymphokine‐activated killer (LAK) cells in WAG rats after hepatic‐artery or jugular‐vein infusion

This study deals with the biodistribution of syngeneic radiolabeled lymphokine‐activated killer (LAK) cells in Wag rats after infusion via the hepatic artery or the jugular vein. The biodistribution of IIIIndium‐labeled LAK cells was evaluated using serial whole‐body gamma camera imaging. Furthermore, we investigated 2 factors that might influence the biodistribution of these effector cells: purity of LAK cells and administration of interleukin‐2 (IL‐2). After injection of IIIIndium‐labeled LAK cells via the hepatic artery or via the jugular vein we could detect important differences in the biodistribution pattern up to 5 hr after injection. LAK cells administered via the jugular vein were all found in the lungs up to 2 hr after injection and then redistributed to the liver and to the spleen. LAK cells administered via the hepatic artery were all found in the liver after injection and redistributed after 2 hr mainly to the spleen. About 8 hr after injection we could no longer detect any differences in the biodistribution pattern according to the route of administration. Biodistribution was followed for up to 72 hr after injection but the pattern showed no change after 8 hr, whichever the route of administration. A purified adherent‐LAK population, a large granular lymphocyte culture with only 6% T cells, showed the same distribution pattern as standard LAK cells (40% T cells). Infusion of 40,000 units of IL‐2 per day, starting 3 days before and continuing after administration of radio‐labeled LAK cells, accelerated the redistribution of these cells by both routes of administration. We conclude that up to 2 hr after local infusion, a high concentration of LAK cells in the first capillary bed can be obtained. Therefore, local administration of LAK cells may be more effective against tumors. © 1992 Wiley‐Liss, Inc.

[1]  E. Wisse,et al.  Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and kupffer cells in the liver of rats treated with continuous infusion of interleukin‐2 , 1990, Hepatology.

[2]  P. Kuppen,et al.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. , 1990, British Journal of Cancer.

[3]  J. Hiserodt,et al.  In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. , 1990, Cellular immunology.

[4]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[5]  S. Rosenberg Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review. , 1989, Cancer treatment reviews.

[6]  H. Wallny,et al.  A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes , 1989, The Journal of experimental medicine.

[7]  F. Ramsdell,et al.  Generation of lymphokine-activated killer cell activity from non-NK precursor cells. , 1988, Cellular immunology.

[8]  A. Maghazachi,et al.  In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. , 1988, Cellular immunology.

[9]  R. Puri,et al.  Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. , 1988, Journal of the National Cancer Institute.

[10]  A. Maghazachi,et al.  Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells , 1988, The Journal of experimental medicine.

[11]  A. Eggermont,et al.  The requirements for successful immunotherapy of intraperitoneal cancer using interleukin‐2 and lymphokine‐activated killer cells , 1987, Cancer.

[12]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[13]  S. Rosenberg,et al.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. , 1986, Journal of immunology.

[14]  S. Rosenberg,et al.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.

[15]  S. Rosenberg,et al.  Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. , 1985, Journal of immunology.

[16]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[17]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[18]  D. Mathisen,et al.  The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.

[19]  Ackerman Nb,et al.  The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. , 1970 .

[20]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.